Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company that designs and develops novel small molecule medicines using its computational drug discovery engine and machine-learning–based predictive modeling. Its pipeline includes the clinical-stage HPK1 inhibitor NDI-101150 for solid tumors and a diverse portfolio of preclinical programs focused on cancer, autoimmune conditions and metabolic diseases, including WRN and an undisclosed autoimmune target. Nimbus is advancing novel targeted therapies that activate AMPK through a collaboration with Eli Lilly. The company will use proceeds from its recent financing to advance multiple preclinical programs into and through early clinical development and to continue clinical development of NDI-101150. Nimbus emphasizes integrating computational chemistry with high-tech structural biology tools to tackle difficult-to-drug targets. The company is headquartered in Boston, MA. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company that combines computational technologies and machine learning to design novel small-molecule medicines. The company focuses on programs across inflammatory and autoimmune disorders, cancer, and metabolic diseases and has three internally discovered compounds that have advanced into clinical trials. Lead clinical programs include NDI-034858, an oral allosteric TYK2 inhibitor in Phase 2b for plaque psoriasis and psoriatic arthritis (with planned Phase 3 initiation), and NDI-101150, an HPK1 inhibitor in Phase 1/2 for solid tumors. Nimbus is also advancing preclinical programs targeting Cbl-b and WRN and continues discovery efforts across multiple targets. The recent financing is intended to fund completion and initiation of multiple clinical trials and ongoing preclinical and discovery work. Nimbus is headquartered in Cambridge, MA. Nimbus Therapeutics designs potent, selective small-molecule compounds using a structure-based drug discovery engine to target proteins that drive pathology in prevalent diseases. The company’s LLC/subsidiary architecture enables diverse partnerships to advance programs. Its pipeline includes a novel allosteric TYK2 inhibitor with compelling data and an HPK1 inhibitor candidate slated for first-in-human studies in solid tumors. Nimbus plans multiple Phase 2 clinical studies of the TYK2 inhibitor in 2021 and 2022 and expects to begin IND-enabling studies on two novel agents in 2022. The financing will also accelerate preclinical programs across oncology and immunology. Nimbus is headquartered in Cambridge, Mass. Nimbus Therapeutics is a Cambridge, Mass.-headquartered biotechnology company that designs small-molecule medicines using a structure-based drug discovery engine. Its approach focuses on potent and selective small-molecule compounds targeting proteins that drive pathology in prevalent diseases, and the company uses an LLC/subsidiary architecture to enable diverse partnerships. Nimbus announced a $60 million private financing from RA Capital Management and BVF Partners to accelerate its pipeline. The funds will support advancing its Phase 1 allosteric TYK2 inhibitor into Phase 2 early next year, moving its HPK1 inhibitor into the clinic next year, and advancing its preclinical portfolio. RA Capital's Laura Stoppel will join the Nimbus board as part of the financing. Company leadership said the financing defines a pathway for future investment and that they expect to bring on additional new investment in 2021 with continued success. Nimbus Therapeutics applies deep computational expertise across drug discovery and development to design novel treatments for metabolic disease, cancer and immune‑inflammatory disorders. The company combines massive computational‑chemistry capabilities with founding partner Schrödinger and leverages structural biology, cryo‑EM, and machine‑learning–augmented ADMET prediction. Its current portfolio includes Tyk2 inhibitors and STING antagonists partnered under an immunology alliance with Celgene, and a wholly owned STING agonist program with compelling preclinical small‑molecule data. Nimbus plans to expand discovery into new high‑value targets that overlap biological mechanisms in immunology, oncology, and metabolic disease, and to advance several undisclosed target programs toward the clinic in the next few years. The company announced $65 million in new capital to accelerate pipeline progress and expand discovery efforts. Proceeds from this financing together with business‑development activity have helped Nimbus remain a privately held LLC and build a nine‑figure balance sheet to support rapid advancement and partnerships. The company is headquartered in Cambridge, Massachusetts.

Total raised

$632M

Funding rounds

8

Latest round

Equity

Latest activity

Sep 2023